# Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

> **NCT03703882** · PHASE3 · COMPLETED · sponsor: **Catabasis Pharmaceuticals** · enrollment: 131 (actual)

## Conditions studied

- Muscular Dystrophy, Duchenne

## Interventions

- **DRUG:** Edasalonexent
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03703882
- **Lead sponsor:** Catabasis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-02
- **Primary completion:** 2020-09-22
- **Final completion:** 2020-09-22
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03703882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03703882, "Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03703882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*